Estimates Revisions Summit Therapeutics Inc.
Stocks
SMMT
US86627T1088
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.66 USD | -8.81% |
|
-1.09% | -21.90% |
| 25/07 | Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept | MT |
| 24/07 | Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- SMMT Stock
- Consensus Summit Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
